FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPE	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses) 1. Name and Address of Reporting Person* L. The Company of the Compa															5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Lam Thomas S.					Apollo Medical Holdings, Inc. [AMEH]										_X_ Director 10% Owner						
(Last) (First) (Middle) 1668 S. GARFIELD AVE., 2ND FL. (Street)					3. Date of Earliest Transaction (Month/Day/Year) 09/30/2019									X_Officer (give title below) Other (specify below) Co-Chief Executive Officer							
					4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person							
ALHAMBR.	A, CA	91801												FG	orm filed by	More than One	Reporting Perso	n			
(City)		(State)	(Zip)				T	able I	- No	n-Deri	vative S	ecuritie	s Acqu	ired,	Disposed	of, or Bene	ficially Own	ied			
(Instr. 3)		2. Transacti Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		Date, if	Code (A (Instr. 8)			A) or Di	ecurities Acquired or Disposed of (D) str. 3, 4 and 5)			Owned Following Reported Transaction(s)			6. Ownership Form:	Beneficial			
						y/ Y ear)	Code		V	Amount	(A) or (D)	Price									
Common Stock		09/30/20	09/30/2019				A			8,883	A		58,8	883			D				
Reminder Den	ort on a se	eparate line for each	alass of som	ritios b	nonoficio:	1117.0	wnod di	rootly	or ind	liroctly											
Keminder, Kept	on on a se	eparate fine for each	ciass of sect	iriues t	benencia	шу с	owned di	rectry	P	erson	s who						tion contai	ned SEC	C 1474 (9-02		
															espond control n	unless the umber.	e form				
			Tal	ble II -	Derivat	tive S	Securitie	s Acq	uired	l, Dispo	sed of,	or Bene	ficially	Own	ed						
1 75:4 6 0		2 T .:	24 5		0/1	ıts, c	alls, war						- 	1		0 D : 0	0.31 1	6 10	11.37		
1. Title of Derivative Security (Instr. 3) Price of Derivativy Security	exercise ee of rivative			ate, if	f Transaction of Deri Code Securit			rivative Expiration Date (Month/Day/Ye (posed)			Date	e of Un ear) Secur		Title and Amount Underlying urities ttr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported	Owner Form o	tive Owner (y: (D)		
							and 5)	,, -,									Transaction(s) (Instr. 4)				
									Date		Expira	ition			Amount or			(IIISII.	+)		
						Code V		(D)		rcisable		*			Number of Shares						
	17.62	09/30/2019			A ⁽²⁾		39,189	9		(2)	09/30	0/2024	Com		39,189	\$ 0	39,189	D			
Reportir	ng Ov	wners																			
	-8 -											_									
Director			Relationships																		
		Director	10% Owner		Officer						Other										
Lam Thomas S. 1668 S. GARFIELD AVE., 2ND FL. ALHAMBRA, CA 91801			X		Co-Chief			Executive Officer			cer										

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

**Signature of Reporting Person

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Restricted shares of Apollo Medical Holdings, Inc.'s (the "Company") Common Stock granted under the Company's 2015 Equity Incentive Plan, subject to vesting one-third after year one (on September 30, 2020), one-third after year two (on September 30, 2021), and the final one-third after year three (on September 30, 2022).

Date

Stock option to purchase the Company's Common Stock granted under the Company's 2015 Equity Incentive Plan, which stock option will vest and become exercisable one-third after year one (on September 30, 2020), one-third after year two (on September 30, 2021), and the final one-third after year three (on September 30, 2022), subject to expiration on the date (2) that is five years from the date of grant (i.e., on September 30, 2024). The exercise price for each share subject to the stock option granted shall be set at the closing price of the Company's Common Stock on the date of grant (i.e., September 30, 2019).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.